M&A Deal Summary |
|
|---|---|
| Date | 2014-12-04 |
| Target | PneumRx |
| Sector | Medical Products |
| Buyer(s) | BTG |
| Sellers(s) |
Adams Street Partners
Telegraph Hill Partners Alta Partners |
| Deal Type | Add-on Acquisition |
| Deal Value | 475M USD |
| Advisor(s) | J.P. Morgan Securities (Financial) Wilson Sonsini Goodrich & Rosati (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1948 |
| Sector | Medical Products |
| Employees | 1,182 |
| Revenue | 823M USD (2018) |
BTG plc which develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases, as well as acute care pharmaceuticals. BTG has three key businesses, the largest of which is its Interventional Medicine portfolio which encompasses several peripheral interventional product lines. The interventional oncology franchise includes the TheraSphere® Y-90 radiotherapy microspheres and the GALIL™ cryoablation system, used to treat patients with liver, kidney, and other cancers. More than 840,000 people are expected to be diagnosed with liver cancer in 2018, and that number is expected to grow to 1.1 million by 2030. Kidney cancer is among the 10 most common cancers in both men and women.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 6 |
| Sector (Medical Products) | 2 of 5 |
| Type (Add-on Acquisition) | 1 of 4 |
| State (California) | 1 of 2 |
| Country (United States) | 1 of 4 |
| Year (2014) | 1 of 1 |
| Size (of disclosed) | 1 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-07-15 |
Nordion - Targeted Therapies Division
Ottawa, Ontario, Canada Nordion, Inc. - Targeted Therapies Division manufactures and markets medical devices for treatment of inoperable primary liver cancer and metastatic liver cancer. The division is located in Ottawa, Canada. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-05-06 |
Galil Medical
Arden Hills, Minnesota, United States Galil Medical, Inc. is a provider of medical products for cryoablation solutions. |
Buy | $85M |
| Category | Asset Manager |
|---|---|
| Founded | 1972 |
| PE ASSETS | 26.0B USD |
| Size | Mega |
| Type | Sector Agnostic |
Adams Street Partners is a diversified, global investment firm that targets direct, fund of funds, and secondary investments. Adams' direct investing group covers co-investments in buyout transactions, as well as growth equity and venture capital commitments. The direct buyout and growth equity team looks to commit $5 to $30 million per transaction. For venture related investments, commitments of $5 to $20 million are provided to companies in the technology, life sciences and technology enabled services sectors. Typically, target companies have received prior financing from early stage venture firms and are seeking additional capital to fund product development and commercialization. Adams Street Partners was formed in 1972 and is based in Chicago, Illinois.
| DEAL STATS | # |
|---|---|
| Overall | 56 of 95 |
| Sector (Medical Products) | 9 of 9 |
| Type (Add-on Acquisition) | 28 of 51 |
| State (California) | 27 of 41 |
| Country (United States) | 52 of 87 |
| Year (2014) | 11 of 11 |
| Size (of disclosed) | 7 of 20 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-12-04 |
Maxwell Health
New York, New York, United States Maxwell Health is a SaaS-enabled online benefits service that provides information about health care and insurers. Maxwell Health was founded in 2012 and is based in New York, New York. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-01-01 |
Yeahka
Shenzhen, China Yeahka operates payment-based technology platform that provides payment and business services to merchants and consumers in China. It offers one-stop payment services, which include app-based and traditional payment services comprising mobile payment and bank card acquiring products, as well as an intelligent risk control platform for controlling and managing mobile payments. Yeahka was founded in 2011 and is based in Shenzhen, China. |
Buy | - |
| Category | Venture Capital Firm |
|---|---|
| Founded | 2001 |
| Size | Middle-Market |
| Type | Sector Focused |
Telegraph Hill Partners is a specialist private equity firm focused on investing in later-stage life science, medical device, and healthcare companies. Prospective companies should be at or near profitability and demonstrate success. Other areas of interest within the healthcare sector include life science technologies, chemistry/reagent suppliers, and information management. Telegraph Hill Partners was formed in 2001 and is based in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 18 of 28 |
| Sector (Medical Products) | 10 of 14 |
| Type (Add-on Acquisition) | 15 of 23 |
| State (California) | 12 of 18 |
| Country (United States) | 18 of 27 |
| Year (2014) | 3 of 3 |
| Size (of disclosed) | 1 of 13 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-09-29 |
SAGE Labs
St. Louis, Missouri, United States SAGE Labs, Inc. is a provider of next-generation research models, including knockout rat models, and extensive support services. |
Sell | $48M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-01-01 |
Magstim
Whitland, United Kingdom Magstim is a provider in the research, development, manufacture, and marketing of medical and research devices within the neurological and surgical fields. Magstim was founded in 1990 and is based in Whitland, United Kingdom. |
Buy | - |
| Category | Venture Capital Firm |
|---|---|
| Founded | 1996 |
| PE ASSETS | 2.6B USD |
| Size | Large |
| Type | Sector Focused |
Alta Partners is a venture capital firm that targets investments in early and later stage life science companies, including biopharmaceuticals, medical technology, and information technology businesses. Alta was formed as an early stage investor but has since expanded its investment range to provide later stage growth capital to private and young public companies. Alta was established in 1996 and is headquartered in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 74 of 84 |
| Sector (Medical Products) | 7 of 8 |
| Type (Add-on Acquisition) | 43 of 45 |
| State (California) | 35 of 41 |
| Country (United States) | 66 of 74 |
| Year (2014) | 10 of 10 |
| Size (of disclosed) | 8 of 23 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-07-24 |
Immune Design
Seattle, Washington, United States Immune Design Corp. is a biotechnology company focused on developing a broad platform of novel vaccines (both therapeutic and prophylactic) for the treatment of infectious disease. The Company's technologies regulate immunity by targeting dendritic cell responses with combinations of proprietary viral vectors, TLR agonists, and adjuvants. Immune Design was founded in 2008 and is based in Seattle, Washington. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-03-24 |
ABIONYX Pharma
Balma, France ABIONYX Pharma is an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies for the treatment of cardiovascular and metabolic diseases. ABIONYX Pharma was founded in 2005 and is based in Labege, France. |
Sell | - |
